Arcturus Therapeutics Holdings Inc. (ARCT) analyst actions
Rating and price-target actions on ARCT in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the ARCT overview →
3 measured ARCT analyst action events.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Arcturus Therapeutics Holdings Inc. (ARCT) And Encourages Stockholders to Reach Out | Press release | +0.36% | +1.72% | |
| Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial | Press release | -2.25% | -4.92% | |
| Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency | Press release | +2.85% | +8.04% |
Keep exploring
More ARCT: earnings → · SEC filings → · ARCT overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| PRINCIPIA BIOPHARMA INC COMMON (PRNB) | 282 | +0.23% | 59% |
| Rigel Pharmaceuticals, Inc. (RIGL) | 281 | -0.46% | 42% |
| CORREVIO PHARMA CORP ORDINARY SHARES (CORV) | 279 | 0.00% | 44% |
| Can-Fite Biopharma Ltd American Depositary Shares, each representing two (2) Ordinary Shares (CANF) | 278 | -0.48% | 36% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.